Welcome to our dedicated page for Northview Acquisition news (Ticker: NVACR), a resource for investors and traders seeking the latest updates and insights on Northview Acquisition stock.
NorthView Acquisition Corp. Rights (NVACR) are tied to NorthView Acquisition Corp., a Delaware-incorporated special purpose acquisition company whose securities have been listed on the Nasdaq Global Market. News related to NVACR often reflects broader corporate developments at NorthView, including its progress toward completing an initial business combination and its regulatory and listing status.
Press releases describe NorthView as a blank check company formed to pursue a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Notable announcements include the pricing and closing of its initial public offering of units, the automatic separation of those units into common stock, rights and warrants, and the independent listing of the rights under the symbol NVACR.
Another key news theme involves NorthView’s proposed business combination with Profusa, Inc., a digital health company focused on tissue-integrated biosensors and real-time biochemical monitoring. NorthView has announced the signing of a definitive business combination agreement with Profusa and the filing of a registration statement on Form S-4 with the SEC that contains a preliminary proxy statement/prospectus describing the proposed transaction.
In addition, NorthView has issued multiple notices regarding compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the SEC. These releases discuss deficiency notices from Nasdaq, exceptions granted to regain compliance, and the company’s stated intention to work diligently to file required Quarterly Reports on Form 10-Q within specified timeframes. Together, these items form the core of the news flow that investors and traders monitoring NVACR can review to understand the status of the SPAC, its combination plans, and its exchange listing obligations.
NorthView Acquisition (NVAC) has received a delisting notice from Nasdaq due to failing to complete an initial business combination within the required 36-month timeframe. The company's securities, including Common Stock, Rights, and Warrants, will be suspended from trading on Nasdaq starting December 27, 2024. NVAC plans to transition its securities to the OTC market under the same ticker symbols.
The delisting does not affect NVAC's previously announced business combination with Profusa Inc. Both companies continue working towards closing the deal, after which the merged entity will apply for a new Nasdaq listing. NVAC will maintain its status as a reporting entity under the Securities Exchange Act of 1934.
NorthView Acquisition (NVAC) has received a notice from Nasdaq for non-compliance with listing rules due to failing to file its Form 10-Q for Q3 2024. While this has no immediate impact on the company's Nasdaq listing, NVAC has 60 calendar days to submit a compliance plan. If accepted, Nasdaq may grant up to 180 days from the original due date to regain compliance. The company expects to file the required Form 10-Q within the initial 60-day period, which would resolve the compliance issue without needing a formal plan. If Nasdaq rejects the plan, NVAC can appeal to a Nasdaq Hearings Panel.
NorthView Acquisition (Nasdaq: NVACU) has received an exception from Nasdaq to regain compliance with listing rules. The company must file its Quarterly Reports on Form 10-Q for Q1 and Q2 2024 by October 14, 2024 to avoid potential delisting. This exception allows NorthView to address its failure to timely file required periodic financial reports with the SEC, as mandated by Nasdaq Listing Rule 5250(c)(1). The company is working diligently to meet the deadline and maintain its listing status. If NorthView fails to comply, it may face delisting proceedings but would have the opportunity to appeal to a Hearings Panel.
NorthView Acquisition (Nasdaq: NVAC) announced it received a notice from Nasdaq due to not filing its Form 10-Q for the period ending March 31, 2024, making the company non-compliant with Nasdaq Listing Rule 5250(c)(1). This notice does not immediately affect the company's Nasdaq listing. NorthView has 60 days to submit a compliance plan to Nasdaq, which could grant up to 180 days to regain compliance. If the plan is not accepted, the company can appeal to a Nasdaq Hearings Panel. NorthView is working to file the Form 10-Q within 60 days to avoid submitting a compliance plan.
NorthView Acquisition Corp (Nasdaq: NVAC) has filed a Registration Statement on Form S-4 with the SEC, marking a significant step in its business combination with Profusa, Inc. The filing, made on January 25, 2023, includes a preliminary proxy statement and prospectus about the merger agreement reached on November 7, 2022. The proposed transaction aims to complete by the second quarter of 2023, pending shareholder approval and regulatory conditions. Profusa specializes in advanced tissue-integrated biosensors for real-time biochemical monitoring, promising to innovate personalized medicine.
NorthView Acquisition Corp. (Nasdaq: NVAC) has announced a definitive business combination with Profusa, Inc., a digital health company focused on personalized medicine, as of November 7, 2022. This merger will transition Profusa into a publicly listed company, with NorthView being renamed to Profusa Inc. The deal is expected to yield an estimated pro forma equity valuation of $264 million, assuming 80% redemptions. The transaction aims to bolster Profusa's growth, facilitating the launch of its innovative biosensor technology for real-time health monitoring.
NorthView Acquisition Corp. (NASDAQ: NVACU) announced that, effective January 21, 2022, its units will cease trading, with the common stock, rights, and redeemable warrants commencing separate trading. The common stock, rights, and warrants will trade under the symbols NVAC, NVACR, and NVACW, respectively. This mandatory separation process requires no action from unit holders. Each unit comprises one share of common stock, one right, and half a warrant, rounding down any fractional warrants in distribution. NorthView seeks acquisition targets in the healthcare sector valued between $500 million to $2 billion.
NorthView Acquisition Corp. (NASDAQ: NVACU) has successfully closed its initial public offering, raising approximately $189.75 million by offering 18,975,000 units at $10.00 each. The units, which started trading on December 20, 2021, consist of one share of common stock, one right, and half a warrant. Once separated, they will trade under the symbols NVAC for common stock, NVACR for rights, and NVACW for warrants. This funding will support future mergers or acquisitions, primarily in the healthcare sector.
NorthView Acquisition Corp. (NASDAQ: NVACU) has priced its initial public offering of 16,500,000 units at $10.00 each, set to begin trading on December 20, 2021. Each unit comprises one share of common stock, one right, and half a redeemable warrant. The rights allow for a fractional share upon completion of a business combination, while warrants will permit stock purchases at $11.50 per share. The offering, managed by I-Bankers Securities and Dawson James Securities, is expected to close around December 22, 2021, subject to standard conditions.